{"anticipatedPostingDate":"2028-06","denomUnitsSelected":"Participants","description":"Incidence and severity of treatment emergent adverse events (TEAEs) will be reported. Any adverse event occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or until the start of subsequent anticancer therapy (if earlier), is considered to be treatment emergent.","reportingStatus":"NOT_POSTED","timeFrame":"Approximately 60 months","title":"Incidence and Severity of Adverse Events (AEs)","type":"SECONDARY"}